Evidence map›Paper›PMID 32743365›Full record

ArticleIJU case reports2019

Expression of PD-L1 and CTLA-4 in female urethral carcinoma.

Sahoko Ninomiya, Takashi Kawahara, Taku Mochizuki, Yukari Ishiguro, Yasuhide Miyoshi, Masako Otani, Masahiro Yao, Hiroshi Miyamoto, Hiroji Uemura

Open access · goldAbstract readCase Reports
In one paragraph

Article in IJU case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sahoko NinomiyaDepartments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.
Takashi KawaharaDepartments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.ORCID 0000-0002-7049-3379
Taku MochizukiDepartments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.
Yukari IshiguroDepartments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.
Yasuhide MiyoshiDepartments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.
Masako OtaniDivision of Diagnostic Pathology Yokohama City University Medical Center Yokohama Kanagawa Japan.
Masahiro YaoDepartment of Urology Yokohama City University Graduate School of Medicine Yokohama Kanagawa Japan.
Hiroshi MiyamotoDepartments of Pathology and Laboratory Medicine, Urology, and Oncology University of Rochester Medical Center Rochester New York USA.
Hiroji UemuraDepartments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.
Yokohama City University Medical Center · JPUniversity of Rochester Medical Center · USYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough the tumors are often easily detected, a considerable number of patients with female urethral carcinoma are diagnosed in an advance stage. Thus, no evidence-based therapeutic approach has been established. We herein report our experience in the treatment of three female patients with urethral carcinoma. We also examined the expression of PD-L1 and CTLA-4. CASE PRESENTATION: Three female patients pathologically diagnosed with urethral carcinoma, including urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma, between 2013 and 2017 were analyzed in this study. Two patients underwent urethrectomy with cystostomy. Immunohistochemistry was performed to assess the levels of PD-L1 and CTLA-4 expression in patients with urethral carcinoma. Eleven control cases of urethral carcinoma tissue were also stained.

conclusionThis study revealed the expression of PD-L1 and CTLA-4 in female urethral carcinomas.

Indexed as

CTLA‐4female urethral cancerimmunocheckpoint inhibitorPD‐L1

Identifiers

PMID32743365
PMCPMC7292119
OpenAlexW2901494430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.